Mycobacterium tuberculosis is cause of the world's most deadly infectious disease. Efforts are underway to target the methionine biosynthesis pathway, as it is not part of the host metabolism. The homoserine transacetylase MetA converts L-homoserine to O-acetyl-Lhomoserine at the committed step of this pathway. In order to facilitate structure-based drug design, we determined the high-resolution crystal structures of three MetA proteins, including M. tuberculosis (MtMetA), Mycolicibacterium abscessus (MaMetA), and Mycolicibacterium hassiacum (MhMetA). Comparison to other homoserine transacetylase family-members reveals a high degree of structural conservation. Utilizing homologous structures with bound cofactors, we analyzed the potential ligandability of MetA. The deep active-site tunnel surrounding the catalytic serine yielded a number of consensus clusters during mapping, suggesting that
Introduction
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB), a persistent global health threat. In 2017, TB was responsible for the deaths of 1.3 million HIV-negative people and an additional 300,000 deaths among the HIV-positive population. 1, 2 Approximately 10 million people contracted TB that same year. 2 Despite increased focus since WHO declared TB as a global health emergency back in 1993, progress towards fighting it has been mixed. It ranks among the top ten causes of death among the world's population and is the single mostly deadly infectious disease, claiming more lives than HIV/AIDS. 2 Survivors of TB infections can also suffer significantly reduced quality of life. 3 The bacilli Calmette-Guerin (BCG) vaccine is capable of protecting children from the most sever forms of TB and is still the preferred method for disease control. However, no vaccine is capable of preventing TB infection in adults either pre or post exposure. 4 Existing anti-TB therapy requires treatment of six months or more with a combination of multiple therapeutic agents: rifampicin, ethambutol, isoniazid and pyrazinamide. Treatment with first-line drugs leads to a cure rate of about 85% of those with drug-susceptible TB strains. 2 The side effects and length of these treatments has led to compliance issues. This fact, combined with the lack of care in some areas of the world, has spurred the development of multi-drug resistant TB (MDR-TB); 6% of these MDR-TB cases are so antibiotically hardened that they are classified as extensively drug-resistant TB (XDR-TB). 2 MDR-TB and XDR-TB infections have limited treatment options which are not always successful, particularly in the case of immunocompromised patients and XDR-TB. Current therapeutic regimens are often toxic, require long durations of treatment time and are estimated to increase treatment costs 8 to 15-fold compared to treating normal TB infections. 5 This difference is even more extreme in the case of XDR-TB with costs being 25 to 32-times higher. There is a clear need for effective, low-cost TB therapies with orthogonal activity to current antibiotic options.
MetA is a L-homoserine O-acetyltransferase, commonly also referred to as a homoserine transacetylase (HTA) and is a key enzyme in the biosynthesis of methionine and threonine ( Fig.   1 ). 6 It catalyzes the conversion of L-homoserine to O-acetyl-L-homoserine (OAHS) by transfer of an acetyl group from Acetyl-CoA to the γ -hydroxyl of homoserine. This transfer uses a doubledisplacement mechanism facilitated by a Ser-His-Asp catalytic triad. 7 OAHS is an important precursor to methionine as well as other bacterial metabolites, such as S-Adenosyl-L-methionine (SAM). The modification of L-homoserine is a committed step in methionine and SAM synthesis.
Bacterial studies have shown that deletion of met2 gene, which encodes an analogous HTA, is lethal without methionine supplementation. 8, 9 Further studies using immunocompetent and immunocompromised mice demonstrate that deletion of metA generates auxotrophic mutants unable to establish infection. 10 If starved of threonine and methionine in vitro, Mtb Δ metA dies quickly. Further, Δ metA mutant strain is unable to proliferate inside of human macrophages.
Together, these data suggest that Mtb is unable to scavenge biosynthetic intermediates from the host for methionine synthesis, making for a uniquely exploitable vulnerability for the development of anti-bacterial agents.
Efforts are already underway to inhibit HTA in Cryptococcus neoformans for use as an antifungal agent. 8 In addition, targeting of a similar pathway for aspartate production has already yielded some promising selective inhibitors for Streptococcus pneumoniae and Vibrio cholerae. 11 A similar structurally guided approach to discovering specific inhibitors is an attractive alternative to traditional antibiotic killing of MDR-TB and XDR-TB.
Here we report the structures of three homologous MetA enzymes from Mycobacterium tuberculosis (MtMetA), Mycolicibacterium abscessus (MaMetA), and Mycolicibacterium hassiacum (MhMetA) and compare them to previously solved structures of HTAs in order to begin development of selective inhibitors of MtMetA via a structurally based approach. Using the MtMetA structure as a guide, we also elucidate the druggability of the enzyme and propose that it is an excellent candidate for small molecule drug discovery.
Results

Overview of mycobacterial MetA structures
MhMetA consists of 374 residues, while MaMetA is slightly larger at 384 residues, and MtMetA the smallest at 366 residues. The solved crystal structures include residues 13-372 from MhMetA ( Fig. 2A ) and 13-379 from MaMetA (Fig. 2B ), and 7-373 from MtMetA (Fig. 2C ). Two copies of each monomer exist in the asymmetric unit of all three structures. MetA can be divided into two distinct structural domains, the catalytic domain and the lid domain.
The organization of the catalytic domains' fold marks MetA as members of the α /β-hydrolase super-family. It is a highly diverse family that includes proteases, lipases, and esterases among many others. [12] [13] [14] A canonical 8-stranded β -sheet fold with twisted, parallel topology forms the core of α /β-hydrolases. 15 Several α -helices flank either face of this fold, though their number and location is different depending on the of specific protein. The catalytic domain comprises residues 15-181, 297-372 of MhMetA (Fig. 2D ), residues 17-183, 304-379 of MaMetA ( Fig. 2E) and residues 17-181, 311-372 of MtMetA (Fig. 2F ). The catalytic domain contains the active site tunnel with its a canonical catalytic triad.
Assembly occurs at an anti-parallel four-helix bundle motif (αL1 and α L3) in the lid domain. The total interface area of the dimer is ~1700 Å 2 . 16 Two additional helices help to strengthen the interaction with hydrogen bonds and van der Waals contacts (αL4 and α L5). Like other previously studied HTAs, MetA forms solution dimers at this interface. These dimers have been shown to be physiologically relevant in other HTAs and are likely important for MetA as well. 7 The lid domain comprises residues 184-285 of both MhMetA and MtMetA, and residues 187-292 of MaMetA, between β 8 and α 5 (Fig. 3A) . 
Catalytic Mechanism
The catalytic triad of Nucleophile-His-acid is the α /β-hydrolase family's most conserved feature.
Just as in other known HTA structures, MtHTA, MhHTA and MaHTA contain a serine, aspartic acid, and histidine in the active site. HTAs have a serine between β 7 and α 3, an aspartic acid on the loop between β 9 and α 6, and histidine on α 7 for these residues. For MtHTA and MhHTA, Ser157, Asp320, and His350 form the active site; MaHTA's triad is comprised of Ser160, Asp327, His357 (Fig. 4A ). The catalytic serine sits at the end of a deep catalytic tunnel ( Fig 4B) .
Studies in H. influenzae and Schizosaccharomyces pombe suggest that the mechanism of
HTAs is based on a "ping-pong" reaction. 7, 18 In the proposed mechanism, acetate is first transferred to serine from acetyl-CoA in the "ping" step to create an acetyl-enzyme intermediate through an attack of the acetyl-CoA thioester bond. In the "pong", L-homoserine breaks down a tetrahedral intermediate of the acetyl-enzyme to complete the transfer to OAH. 17 Histidine and aspartic acid function as bases to activate the serine residue for attack and can also most likely assist in deprotonation of the L-homoserine. 18 The active site residues of MtMetA, MhMetA, MaMetA, and MsHTA have similar geometry to other bacterial and fungal HTAs. Just as in other structures, the serine sits in a strained conformation at the end of the active site tunnel, ideally positioned for its function as the nucleophile. The histidine and aspartic acid residues are within hydrogen bonding distance for activation of the serine (Fig. 4 ). The active sites of LiHTA and SaHTA show the most deviation.
In the structure, His344 of LiHTA exists in two different conformations with equivalent occupancy. 19 In the SaHTA structure, His296 is more disordered with a high B-factor (B = 72 Å 2 )
for its imidazole ring. 20 
Structural Comparisons to Other HTAs
The overall fold is similar to previously solved HTAs, specifically MsHTA (PDB entry 6IOG) 21 ,
HiHTA (PDB entry 2B61) 22 , SaHTA (PDB entry 4QLO) 20 , LiHTA (PDB entry 2PL5) 19 . The three solved MetAs are most similar in length to MsHTA (374 residues), with LiHTA (366 residues)
and SaHTA (322 residues) being shorter proteins and HiHTA (377 residues) being slightly longer. The major differences lie in the loop lengths and in a few short secondary structural elements. The most notable secondary structure difference occurs in the length of β MtMetA to determine its viability for crystallography, the T m was found to be between 40-41 °C by differential scanning fluorimetry (DSF) between pH 6.9-8.5 in Tris-HCl. There should be is no major hinderance to using native MtMetA protein for future investigation.
Potential Ligandability of MetA
Druggability of a protein is understood to be a measure of relative ease of developing a small molecule which will effectively modulate its activity in vivo. 25, 26 Druggability depends on the pharmacodynamics and pharmacokinetics of the host and the pathogen making it difficult to predict computationally. Ligandability is a necessary condition for druggability, but is a more easily quantified metric for the development of inhibitors. 27 Understanding ligandability, and thus druggability, is critical before embarking on drug discovery, as an estimated 60% of small molecule searches fail to due to the target not being sufficiently druggable. 28, 29 The availability of a high-resolution structures for MetA opens up the possibility of performing direct therapeutic target discovery, provided it proves to be sufficiently ligandable.
The key principle to drug discovery is that biologically active ligands are complimentary in molecular features and shape to the receptor. These can include physiochemical properties such as hydrophobicity, size, and electrostatics as well as the enclosure of the binding pocket and its promiscuity. 30, 31 The inner surface of MetA's active site ranges from neutral to electropositive (Fig. 5A) whereas the external surface of the protein ranges from mostly neutral to somewhat electronegative. Absolute values range from 16.08 k b T e c -1 at the inner side of the active site to -36.8 k b T e c -1 on a solvent exposed loop of the lid domain.
Hydrophobicity is a known important aspect of ligandability. A strictly predominantly hydrophobic pocket might indicate a promiscuous binding site that may accommodate a wide-varying of ligands in different modes, some hydrophobic patches are still nevertheless ideal for ligand design. MetA has a strongly hydrophobic patch ( Fig. 5B ) running along the inside of the activate site tunnel opposite the electropositive region. Binding models for homoserine ( Fig. 5C ) and
acetyl-CoA (Fig. 5D ) were created by hybridizing the MtMetA structures with available MsHTA structures that have been co-crystallized with both substrates 21 in order to better understand their coordination within the binding pocket. While the hydrophobic patch does not appear critical to the recognition of either, its proximity to the catalytic site residues make it an ideal feature to leverage for designing hydrophobic ringed small molecules with flexible tail groups that could orient inside of the cleft similar to acetyl-CoA.
In order to further understand the active site's ligandability, FTMap was utilized. [32] [33] [34] The FTMap algorithm uses a set of small organic probes to computationally sample a protein surface for binding hotspots. Each organic probe is first rigidly docked before being energy minimized. These results when overlaid with the hybrid substrate binding models suggest that MetA is ligandable.
Discussion
All three MetA structures show a high degree of overall similarity to previously studied HTAs from both bacteria and fungi. Differences in enzyme size are accounted for by the length of loop regions. Differences in secondary structural elements arise primarily from variations within these loops. All three solved structures crystallized as dimers at the expected interface and orientation that corresponds to predicted physiologically active assembly.
In addition to sharing overall domain and fold arrangement, the conserved location of the Ser-His-Asp catalytic triad's position within the active site tunnel may help protect the enzyme from covalent modification and deactivation. Engineered β -lactones with hydrophobic tails have already been shown to inhibit the activity of HiHTA in vitro through the formation of adducts.
There may be therapeutic value in modifying their structure to enhance specificity towards Mtb. 35 However, their lack of in vivo inhibition of HiHTA suggests that a more efficacious method for disrupting methionine biosynthesis lies in small molecule inhibitors. These would be less prone to bacterial inactivation and less prone to exclusion by Mtb's complex lipid cell wall. The high degree of structural similarity with previously solved homologs provides an excellent foundation for in silico compound screening and structure driven drug design methodologies.
The FTMap cluster data also provides aid towards a Fragment Based Drug Discovery (FBDD).
Previous research has shown that promising core fragments typically bind in the highest strength CS. 36 While the fragment molecules are too small on their own to have useful affinity, neighboring CS probe structures can be then be linked to the core fragment to build up a high affinity ligand. Furthermore, virtually-linked fragments could be screened in silico against existing chemical homologs using a tool such as ROCs. 37 M. abscessus MetA was initially chosen for study due to its high similar to the Mtb variant.
However, the structure and CS data argue that it might make a good secondary target for drug development. Many compounds that inhibit MtMetA are also likely to have an effect on MaMetA.
M. abscessus is an emerging public-health threat, primarily implicated in pulmonary infections. 38 Cross-species gene transfer has helped to create multidrug-resistant strains, some even showing resistance to TB drugs such as rifampin. 39, 40 In summary, by reporting the first medically relevant MtMetA and MaMetA crystal structures, we hope that new avenues of structure-based drug design will be open for developing targeted and effective therapeutics. 
Experimental procedures
Protein Expression and Purification
Constructs of
Data and Structural Determination
Crystals of each MetA construct were flash frozen in liquid nitrogen after cryoprotection by transfer into the corresponding crystallization solutions supplemented with 20-25% glycerol.
Data from MhMetA and MaMetA crystals were collected at the Stanford Synchrotron Radiation Lightsource beamline 9-2 using Dectris Pilatus 6M detector at 1.000 Å wavelength. Data from
MtMetA crystal were collected at the SER-CAT beamline (22-ID) at the Advanced Photon Source using an Eiger 16M detector at 1.000 Å wavelength. Data were indexed, integrated and scaled using XDS and XSCALE. 41 The structure of MhMetA was determined by molecular replacement using Phaser 42 43 and iterative refinement was done via phenix.refine. 44, 45 Data and refinement statistics are summarized in Table 1 .
Differential scanning fluorimetry (DSF)
The assay was carried out using in a range of buffers using 50 mM Tris-HCl pH 6.9-8. were not significantly different between both servers.
The MtMetA substrate models were created by using a MsHTA structures which has been solved in the presence of acetyl-CoA (PDB entries 6IOH and 6IOI) 21 . Monomers from each structure positioned using rigid-body alignment using Chimera's MatchMaker 46 . Energy minimization on the hybrid structure was then performed using the Molecular Modeling Toolkit and Dock Prep with the AMBER ff14SB forcefield. 47
Data Availability
Atomic coordinates and structure factors of the reported crystal structures have been deposited to the Protein Data Bank with accession codes 5W8O (MhMetA), 5W8P (MaMetA) and 6PUX (MtMetA). 
